返回 
加入收藏
司来帕格治疗肺动脉高压的快速卫生技术评估
x
请在关注微信后，向客服人员索取文件
| 篇名： | 司来帕格治疗肺动脉高压的快速卫生技术评估 |
| TITLE： | Rapid health technology assessment of selexipag in the treatment of pulmonary arterial hypertension |
| 摘要： | 目的 评价司来帕格治疗肺动脉高压（PAH）的有效性、安全性和经济性。方法计算机检索PubMed、Embase、WebofScience、CochraneLibrary、Epistemonikos、SinoMed、中国知网、维普网、万方数据、中国生物医学文献数据库、国内外卫生技术评估机构官方网站及相关数据库，经文献筛选、资料提取、质量评价后，对纳入研究的结果进行描述性分析。结果与结论共纳入7篇文献，包括6篇Meta分析和1篇药物经济学研究。有效性方面，司来帕格可改善患者运动耐量、血流动力学指标，并可降低临床恶化事件发生率和住院治疗率，但静脉/皮下途径的前列环素类似物在改善WHO心功能分级和降低全因死亡率方面的效果更佳（P＜0.05）。司来帕格与其他靶向药物对各项结局指标影响的差异均无统计学意义（P＞0.05）。安全性方面，司来帕格可增加一般不良反应事件的发生率和因无法耐受不良反应停药的发生率（P＜0.05），而与各类靶向药物比较的差异均无统计学意义（P＞0.05）。经济性方面，基于加拿大卫生体系背景，司来帕格治疗PAH不具有经济性；目前缺少基于我国国情的经济学研究。尚需进一步开展司来帕格和前列环素类药物在真实世界中疗效和经济性的对比研究。 |
| ABSTRACT： | OBJECTIVE To evaluate the efficacy ，safety，and economy of selexipag in the treatment of pulmonary arterial hypertension（PAH）. METHODS After literature screening ，data extraction and quality evaluation ，the results of included studies were analyzed descriptively by retrieving PubMed ，Embase，Web of Science ，Cochrane Library ，Epistemonikos，SinoMed， CNKI，VIP，Wanfang data ，CBM，official websites of domestic and foreign health technology assessment institutions and relevant database. RESULTS&CONCLUSIONS A total of 7 literature were included ，involving 6 meta-analysis and 1 pharmacoeconomic study. In terms of efficacy ，selexipag could improve patients ’exercise tolerance and hemodynamic indexes ，and reduced the incidence of clinical worsening events and hospitalization . However，intravenous/subcutaneous administration of prostacyclin analog had better effects in improving WHO functional class and reducing all -cause mortality （P＜0.05）. There were no statistically significant differences in the impact on outcome indexes between selexipag and other targeted agents （P＞0.05）. In terms of safety ， the incidence of adverse drug events and drug withdrawal due to adverse reactions was increased by selexipag （P＜0.05），but there were no significant differences between the effects of selexipag and other targeted drugs on adverse events ，serious adverse events and drug withdrawal due to adverse reactions （P＞0.05）. In terms of economy ，based on the background of Canada ’s health system，it was not economical for selexipag to treat PAH ，and there was a lack of economic research based on China ’s national conditions. Further comparative studies on the efficacy and economics of selexipag and prostacyclins in the real world are needed . |
| 期刊： | 2022年第33卷第20期 |
| 作者： | 董文星，张喆，王江，许汝福，楚明明，张蓉 |
| AUTHORS： | DONG Wenxing，ZHANG Zhe，WANG Jiang，XU Rufu，CHU Mingming，ZHANG Rong |
| 关键字： | 司来帕格；肺动脉高压；快速卫生技术评估 |
| KEYWORDS： | selexipag；pulmonary a rterial hypertension ；rapid health techn ology assessment |
| 阅读数： | 154 次 |
| 本月下载数： | 2 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
